Caris Launches Proprietary AI Insights Signature Which Deepens Understanding of Response to Breast Cancer Patients' Oral Chemotherapy Drug
PR Newswire —
IRVING, Texas, Feb. 24, 2026 /PRNewswire/ -- Caris Life Sciences® (NASDAQ: CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, today announced a new breast cancer signature included in the Caris Molecular Tumor Board Report. The Caris...